Cardiff Oncology, Inc. (CRDF) Tops Q3 EPS by 2c

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

You May Also Be Interested In

• Keefe, Bruyette & Woods Downgrades Bain Capital Specialty Finance (BCSF) to Market Perform
• ICICI Securities Starts Cemindia Projects (CEMPRO:IN) at Buy (1)
• Keefe, Bruyette & Woods Starts Columbia Financial Inc (CLBK) at Outperform